ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme

Glioblastoma multiforme is a devastating and intractable type of cancer. Current antineoplastic drugs do not improve the median survival of patients diagnosed with glioblastoma multiforme beyond 14 to 15 months, in part because the blood–brain barrier is generally impermeable to many therapeutic agents. Drugs that target microtubules (MT) have shown remarkable efficacy in a variety of cancers, yet their use as glioblastoma multiforme treatments has also been hindered by the scarcity of brain-penetrant MT-targeting compounds. We have discovered a new alkylindole compound, ST-11, that acts directly on MTs and rapidly attenuates their rate of assembly. Accordingly, ST-11 arrests glioblastoma multiforme cells in prometaphase and triggers apoptosis. In vivo analyses reveal that unlike current antitubulin agents, ST-11 readily crosses the blood–brain barrier. Further investigation in a syngeneic orthotopic mouse model of glioblastoma multiforme shows that ST-11 activates caspase-3 in tumors to reduce tumor volume without overt toxicity. Thus, ST-11 represents the first member of a new class of brain-penetrant antitubulin therapeutic agents. Mol Cancer Ther; 15(9); 2018–29. ©2016 AACR.

[1]  Y. Negishi,et al.  Enhancement of Blood–Brain Barrier Permeability and Delivery of Antisense Oligonucleotides or Plasmid DNA to the Brain by the Combination of Bubble Liposomes and High-Intensity Focused Ultrasound , 2015, Pharmaceutics.

[2]  Jennifer P. Freeling,et al.  Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood , 2014, AIDS.

[3]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[4]  Stephen S. Taylor,et al.  Mitosis and apoptosis: how is the balance set? , 2013, Current opinion in cell biology.

[5]  Behnam Badie,et al.  Microglia and Macrophages in Malignant Gliomas: Recent Discoveries and Implications for Promising Therapies , 2013, Clinical & developmental immunology.

[6]  Jun Zhu,et al.  Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. , 2013, Cancer discovery.

[7]  K. Mackie,et al.  Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models , 2013, The European journal of neuroscience.

[8]  T. Pawson,et al.  Gravin Is a Transitory Effector of Polo-like Kinase 1 during Cell Division , 2022 .

[9]  Stephen S. Taylor,et al.  The Spindle Assembly Checkpoint , 2012, Current Biology.

[10]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[11]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[12]  Jörg Huwyler,et al.  Computational Prediction of Blood-Brain Barrier Permeability Using Decision Tree Induction , 2012, Molecules.

[13]  Duane D. Miller,et al.  An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site , 2012, Pharmaceutical Research.

[14]  I. Vernos,et al.  Microtubule assembly during mitosis – from distinct origins to distinct functions? , 2012, Journal of Cell Science.

[15]  Stephen Yip,et al.  Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. , 2012, Neuro-oncology.

[16]  R. Stupp,et al.  Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[18]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[19]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[20]  Khalid Shah,et al.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. , 2009, Cancer research.

[21]  P. Lienau,et al.  Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. , 2009, Neuro-oncology.

[22]  K. Jaqaman,et al.  Robust single particle tracking in live cell time-lapse sequences , 2008, Nature Methods.

[23]  G. von Dassow,et al.  MCAK facilitates chromosome movement by promoting kinetochore microtubule turnover , 2007, The Journal of cell biology.

[24]  R. Liebl,et al.  Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells. , 2007, Bioorganic & medicinal chemistry.

[25]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[26]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[27]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[28]  F. Szoka,et al.  Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.

[29]  Erwin G. Van Meir,et al.  Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth , 2004, Clinical Cancer Research.

[30]  H. Hsieh,et al.  BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo , 2004, Cancer Research.

[31]  Yanping Sun,et al.  Volume Reconstruction Techniques Improve the Correlation Between Histological and in vivo Tumor Volume Measurements in Mouse Models of Human Gliomas , 2004, Journal of Neuro-Oncology.

[32]  E. Dekel,et al.  Disruption of cancer cell replication by alternating electric fields. , 2004, Cancer research.

[33]  K. Aldape,et al.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.

[34]  J. Serratosa,et al.  High‐yield isolation of murine microglia by mild trypsinization , 2003, Glia.

[35]  F. Mollinedo,et al.  Microtubules, microtubule-interfering agents and apoptosis , 2003, Apoptosis.

[36]  M. Weller,et al.  P‐Glycoprotein and Multidrug Resistance‐associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells , 2003, Brain pathology.

[37]  U. Vanhoefer,et al.  2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. , 2002, Cancer research.

[38]  T. Beckers,et al.  Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. , 2001, Journal of medicinal chemistry.

[39]  John C Kraft,et al.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. , 2014, Journal of pharmaceutical sciences.

[40]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2011, NeuroRX.

[41]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Hyman,et al.  Preparation of modified tubulins. , 1991, Methods in enzymology.